MY112413A - Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals - Google Patents

Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals

Info

Publication number
MY112413A
MY112413A MYPI94002894A MYPI19942894A MY112413A MY 112413 A MY112413 A MY 112413A MY PI94002894 A MYPI94002894 A MY PI94002894A MY PI19942894 A MYPI19942894 A MY PI19942894A MY 112413 A MY112413 A MY 112413A
Authority
MY
Malaysia
Prior art keywords
pharmaceuticals
preparation
substituted heterocyclic
heterocyclic carboxamides
carboxamides
Prior art date
Application number
MYPI94002894A
Inventor
Klaus Weidmann Dr
Karl-Heinz Baringhaus Dr
Georg Tschank Dr
Martin Bickel Dr
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4337271A external-priority patent/DE4337271A1/en
Priority claimed from DE19944410881 external-priority patent/DE4410881A1/en
Priority claimed from DE19944433928 external-priority patent/DE4433928A1/en
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of MY112413A publication Critical patent/MY112413A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

THE INVENTION RELATES TO COMPOUNDS OF THE FORMULA I,FORMULATO A PROCESS FOR THEIR PREPARATION AND TO THEIR USE AS PHARMACEUTICALS. THE COMPOUNDS ARE EMPLOYED, IN PARTICULAR, FOR INHIBITING COLLAGEN BIOSYNTHESIS AND AS INHIBITORS OF PROLYL HYDROXYLASE AND AS FIBROSUPPRESSIVEAGENTS.
MYPI94002894A 1993-11-02 1994-10-31 Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals MY112413A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4337271A DE4337271A1 (en) 1993-11-02 1993-11-02 ubstd. heterocyclic carboxylic acid amides and their prepn.
DE19944410881 DE4410881A1 (en) 1994-03-29 1994-03-29 Substd. heterocyclic carboxylic acid amides and their prepn.
DE19944433928 DE4433928A1 (en) 1994-09-23 1994-09-23 Substd. heterocyclic carboxylic acid amides and their prepn.

Publications (1)

Publication Number Publication Date
MY112413A true MY112413A (en) 2001-06-30

Family

ID=27205714

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI94002894A MY112413A (en) 1993-11-02 1994-10-31 Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals

Country Status (19)

Country Link
EP (1) EP0650961B1 (en)
JP (1) JPH07228571A (en)
KR (1) KR950014072A (en)
CN (1) CN1107145A (en)
AT (1) ATE149486T1 (en)
AU (1) AU676775B2 (en)
CA (1) CA2134866A1 (en)
CY (1) CY2120B1 (en)
CZ (1) CZ289356B6 (en)
DE (1) DE59401924D1 (en)
DK (1) DK0650961T3 (en)
ES (1) ES2101421T3 (en)
GR (1) GR3023174T3 (en)
IL (1) IL111454A (en)
MY (1) MY112413A (en)
NO (1) NO301880B1 (en)
NZ (1) NZ264821A (en)
PL (1) PL179794B1 (en)
TW (1) TW399046B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides
DE19746287A1 (en) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
FR2803592A1 (en) * 2000-01-06 2001-07-13 Aventis Cropscience Sa NOVEL DERIVATIVES OF 3-HYDROXYPICOLINIC ACID, PROCESS FOR THEIR PREPARATION AND FUNGICIDAL COMPOSITIONS CONTAINING SAME
DE10123573B4 (en) * 2001-05-08 2005-06-02 Schering Ag N-Oxidanthranylamide derivatives and their use as pharmaceuticals
DE10123587B4 (en) * 2001-05-08 2005-04-07 Schering Ag Cyanoanthranylamide derivatives and their use as pharmaceuticals
JP4343681B2 (en) 2001-05-08 2009-10-14 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Cyanoanthranilamide derivatives and their use as pharmaceuticals
DK2298301T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
CN101664409A (en) * 2001-12-06 2010-03-10 法布罗根股份有限公司 Stabilization of hypoxia inducible factor (HIF) alpha
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
MX2007016160A (en) 2005-06-15 2008-03-07 Fibrogen Inc Use of hif 1alfa modulators for treatment of cancer.
BRPI0707302B8 (en) 2006-01-27 2021-05-25 Fibrogen Inc cyanoisoquinoline compounds that act on tissue damage associated with ischemia, hypoxia and anemia, as well as pharmaceutical composition comprising them
BRPI0710527B8 (en) 2006-04-04 2021-05-25 Fibrogen Inc pyrrolo- and thiazolo-pyridine compounds and pharmaceutical composition comprising them
PL3357911T3 (en) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
US8962530B2 (en) 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
AU2008302746B2 (en) * 2007-09-20 2014-07-03 Amgen Inc. 1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders
JP5649584B2 (en) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Thiochromene derivatives as HIF hydroxylase inhibitors
KR101007675B1 (en) * 2010-08-13 2011-01-13 김병두 Plasma spray gun with auxiliary cap and plasma spray system using the same
KR101007674B1 (en) * 2010-08-13 2011-01-13 김병두 High speed spray gun and coating device with auxiliary cap
NO2686520T3 (en) 2011-06-06 2018-03-17
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
MA37825B1 (en) 2012-07-04 2016-06-30 Agro Kanesho Co Ltd Derivative of 2-aminonicotinic acid ester and bactericidal containing it as active principle
EP3219706A1 (en) 2012-07-16 2017-09-20 Fibrogen, Inc. Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
AU2013290438C1 (en) 2012-07-16 2019-01-03 Kyntra Bio, Inc. Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
AU2014209319B2 (en) 2013-01-24 2018-04-19 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
HRP20200615T1 (en) 2013-06-06 2020-07-10 Fibrogen, Inc. PHARMACEUTICAL FORMULATIONS OF HIF HYDROXYLASE INHIBITORS
JP2016521747A (en) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Compositions and methods for the treatment of anemia
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN106146395B (en) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3- hydroxypyridine compound, preparation method and its pharmaceutical applications
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
CA3106385A1 (en) * 2018-09-13 2020-03-19 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (en) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (en) 1990-05-12 1991-11-14 Hoechst Ag OXALYL-AMINOSA-E-LEED DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT FOR INHIBITING THE PROLYL HYDROXYLASE
EP0541042A1 (en) * 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft 2,4- and 2,5-pyridine-dicarboxylic acid derivatives, process for their preparation and their use
JPH07504654A (en) * 1992-03-11 1995-05-25 ナルヘックス　リミテッド Amine derivatives of oxo- and hydroxy-substituted hydrocarbons
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
AU7756494A (en) 1995-05-18
DE59401924D1 (en) 1997-04-10
NZ264821A (en) 1997-02-24
HK1006711A1 (en) 1999-03-12
KR950014072A (en) 1995-06-15
IL111454A0 (en) 1994-12-29
CZ268394A3 (en) 1995-05-17
DK0650961T3 (en) 1997-09-15
PL305646A1 (en) 1995-05-15
TW399046B (en) 2000-07-21
ATE149486T1 (en) 1997-03-15
JPH07228571A (en) 1995-08-29
IL111454A (en) 2001-08-08
NO301880B1 (en) 1997-12-22
EP0650961A1 (en) 1995-05-03
ES2101421T3 (en) 1997-07-01
EP0650961B1 (en) 1997-03-05
CA2134866A1 (en) 1995-05-03
NO944162L (en) 1995-05-03
PL179794B1 (en) 2000-10-31
GR3023174T3 (en) 1997-07-30
CY2120B1 (en) 2002-04-26
CZ289356B6 (en) 2002-01-16
NO944162D0 (en) 1994-11-01
AU676775B2 (en) 1997-03-20
CN1107145A (en) 1995-08-23

Similar Documents

Publication Publication Date Title
MY112413A (en) Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
MY131657A (en) Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
PH31264A (en) Substituted heterocyclic carboxamide esters, and their use as pharmaceuticals.
GEP20033028B (en) Heterocyclic Compounds as Inhibitors of Rotamase Enzymes, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
PL318595A1 (en) Derivatives of phenyloacetic acid, method of and intermediate products for obtaining them and agents containing such derivatives
IL114315A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same for inhibiting phosphodiesterase IV
AU5488498A (en) Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them
HUT71105A (en) Mercaptoacylamino-substituted benzazepines condensed with heterocycles, process for preparing them and pharmaceutical compositions of enkephalinase and ace inhibitor activity containing said compounds
AU2364600A (en) Heteroroaromatic amides as inhibitor of factor xa
GR3036305T3 (en) Chiral methyl phenyl oxazolidinones
MX9800408A (en) Cyclo-oxygenase inhibitor and amidine derivative salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts.
AU2364000A (en) Heterocyclic amides as inhibitors of factor xa
NO984740L (en) Isatin derivatives such as acetylcholinesterase inhibitors and analgesics
AU9066498A (en) Substituted 6-alkylphenanthridines
ES8707538A1 (en) 11-Substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines, a process for their preparation and their use in medicaments.
WO2002014313A3 (en) Novel beta-amyloid inhibitors, method for producing the same and the use thereof as medicaments
CA2218663A1 (en) Benzisoxazole and indazole derivatives as antipsychotic agents
HUP0202988A3 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one derivatives and their use as lipase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0103020A3 (en) Heterocyclic derivatives as fkbp inhibitors, process for their preparation, their intermediates and pharmaceutical compositions containing them
WO1999033825A8 (en) N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositons containing them
EP0657451A3 (en) Pyrrolidine derivatives inhibitors of leukotriene biosynthesis.
ATE206105T1 (en) ALKYKENEDIAMINE DI-OR TRI-ACETIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN COSMETIC COMPOSITIONS
MY112414A (en) Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
ATE228359T1 (en) INHIBITION OF LEUKOTRIE BIOSYNTHESIS USING UREA DERIVATIVES